Kendra Sweet, MD

Kendra Sweet, MD, discusses key findings from the OPTIC trial with ponatinib in chronic myeloid leukemia.

Kendra Sweet, MD, discusses efforts made to mitigate toxicities associated with ponatinib in patients with chronic myeloid leukemia.

Kendra Sweet, MD, discusses treatment selection with TKIs in chronic myeloid leukemia.

Kendra Sweet, MD, an assistant member in the Department of Malignant Hematology at Moffitt Cancer Center, discusses discontinuation of tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia.